ARCUTIS BIOTHERAPEUTICS INC (ARQT)
Health Care · Dermatology / topical biopharmaceuticals · NASDAQ
Arcutis is a commercial-stage dermatology biotech company commercializing ZORYVE, a topical PDE4 inhibitor platform addressing psoriasis, atopic dermatitis, and seborrheic dermatitis across multiple age groups.
What ARCUTIS BIOTHERAPEUTICS INC does
Arcutis is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. The company's lead product, ZORYVE (roflumilast), is a topical and foam formulation of a phosphodiesterase-4 (PDE4) inhibitor approved for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis across multiple age groups and body locations. The company has established a platform for dermatologic product development and has launched multiple ZORYVE formulations and indications in the United States and internationally, including through partnerships with Huadong in Greater China and Southeast Asia, and Sato in Japan.
Themes: ["Dermatology / topical therapies"]
Fundamentals
- Price$28.78 as of 2026-07-09 close
- Market cap$3.6B as of 2026-07-10
- 1-year return+107.1% as of 2026-07-09 close
- Net margin-0.6% as of 2026-07-10
- Gross margin+90.9% as of 2026-07-10
- ROE-1.4% as of 2026-07-10
- Debt / equity0.58 as of 2026-07-10
- Revenue growth (YoY)+95.3% as of 2026-07-10
- Revenue CAGR (3y)+367.3% SEC XBRL
- Beta1.50 as of 2026-07-10
Key risks (from latest filing)
[]
Competitors & peers
- LEO Pharma (psoriasis and dermatology)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.